

## A Population-based Matched-cohort Study on Insertion/Deletion Polymorphism of the *APOBEC3B* gene and Risk of HIV-1

M. Imahashi<sup>1,2</sup>, T. Izumi<sup>3</sup>, J. Imamura<sup>1</sup>, K. Matsuoka<sup>1</sup>, Y. Koyanagi<sup>4</sup>, A. Takaori-Kondo<sup>3</sup>, Y. Yokomaku<sup>1</sup>, T. Naoe<sup>2</sup>, W. Sugiura<sup>1,2</sup>, Y. Iwatani<sup>1,2</sup>

<sup>1</sup>Nagoya Medical Center, Clinical Research Center, Nagoya, Japan, <sup>2</sup>Nagoya University Graduate School of Medicine, Nagoya, Japan, <sup>3</sup>Kyoto University Graduate School of Medicine, Kyoto, Japan, <sup>4</sup>Institute for Virus Research, Kyoto University, Kyoto, Japan

**Background:** The human APOBEC3 (A3) family proteins (A3A-H) potently inhibit replication of HIV-1. In human populations, a high-frequency distribution of the *A3B* deletion genotype is observed. Previously, several groups have reported controversial observations on the effect of *A3B* gene deletion on HIV-1 acquisition and disease progression. Here, in order to verify the effects of *A3B* on HIV-1 infection *in vivo*, we investigated the insertion (I)/deletion (D) polymorphism frequencies of the *A3B* gene in a matched cohort in Japan.

**Methods:** The *A3B* genotype was analyzed by PCR with genomic DNA from blood or buccal membrane. The effect of *A3B* gene deletion on disease progression was evaluated by comparing acquisition of Syphilis, HBV and HCV, as well as CD4<sup>+</sup> T cell counts and viral load before starting cART among three genotype groups; deletion-homozygous (D/D), hemizygous (D/I), and no deletion (I/I) genotypes. Susceptibility to HIV-1 infection was assessed based on the frequencies of three genotypes between the infected and uninfected cohorts. HIV-1 replication kinetics and the infectivity were assayed *in vitro* by using healthy donor CD4<sup>+</sup> T cells. Fischer exact and Mann-Whitney U tests were used for statistics.

**Results:** 228 HIV-1-infected patients of Japanese men who have sex with men (MSM) and 207 uninfected Japanese MSM were enrolled. Our *A3B* genotyping analysis showed no significant difference in the ratio of *A3B* genotype between the infected (D/D 8.3%, D/I 44.7%, and I/I 46.9%) and the uninfected (D/D 8.7%, D/I 39.6%, and I/I 51.7%) cohorts ( $p=.55$ ). In addition, the parameters of disease progression resulted in quite similar frequencies among the three genotype groups. These results suggest no significant effect of *A3B* gene polymorphism on the HIV-1 transmission or the disease progression. Furthermore, the *in vitro* kinetics of HIV-1 replication and the infectivities of the virus in CD4<sup>+</sup> T cells were comparable between D/D and I/I ( $p=.31$  and  $p=.86$ , respectively).

**Conclusion:** Our analysis of a population-based matched cohort showed that loss of *A3B* gene is not associated with the risk of HIV-1 susceptibility and disease progression. The results suggest *in vivo*, *A3B* could play an unknown role, but not in eliminating HIV-1.